Maxcyte (MXCT) Liabilities and Shareholders Equity (2020 - 2026)

Maxcyte (MXCT) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $194.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 15.43% year-over-year to $194.5 million; the TTM figure through Mar 2026 stood at $830.2 million (down 14.37% YoY), while the FY2025 annual figure was $202.5 million, down 15.44% from the prior year.
• Liabilities and Shareholders Equity fell to $194.5 million in Q1 2026 per MXCT's latest filing, from $202.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $291.0 million in Q1 2022 and bottomed at $194.5 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $252.9 million across 5 years, with a median of $257.9 million in 2024.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 211.1% — and 2025, when it retreated 15.44%.
• Maxcyte's Liabilities and Shareholders Equity stood at $286.7 million in 2022, then fell by 6.41% to $268.3 million in 2023, then decreased by 10.74% to $239.5 million in 2024, then slipped by 15.44% to $202.5 million in 2025, then declined by 3.97% to $194.5 million in 2026.
• Business Quant data shows MXCT's Liabilities and Shareholders Equity at $194.5 million in Q1 2026, $202.5 million in Q4 2025, and $213.5 million in Q3 2025.